Studies showing that the combination of atezolizumab (anti-PD-L1) and bevacizumab (anti-VEGF) can significantly improve overall survival has made them first-line therapy for patients with advanced HCC (Donisi et al., 2020; Donne and Lujambio, 2022; Sperandio et al., 2022). This evidence concerns the gene CD274 and hepatocellular carcinoma.